Linked Life Data

2545020

Source:http://linkedlifedata.com/resource/pubmed/id/2545020

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1989-8-8
pubmed:abstractText
We report the results obtained in the treatment of 52 advanced non-small-cell lung cancer patients with the combination chemotherapy VP16 (120 mg/m2 i.v., days 1-2-3), epirubicin (50 mg/m2 i.v., day 1) and procarbazine (100 mg/m2 p.o., days 1 through 8). The courses were repeated every 21 days. No patient had been pretreated. A median of 5 courses was administered. Partial response was obtained in 33% and no change in 21% of patients. Median remission time was 6.5 months, and median survival of responders was 10 months. The best response rate and median survival were obtained in the lowest grade performance status patients and in locally advanced disease patients. Major chemotherapy related toxicities were grade 1-2 leukopenia and grade 2-3 alopecia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0300-8916
pubmed:author
pubmed:issnType
Print
pubmed:day
30
pubmed:volume
75
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
168-70
pubmed:dateRevised
2008-12-12
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer.
pubmed:affiliation
Istituto di Clinica Oncologica e Ricerca sui Tumori, Università degli Studi, Messina, Italy.
pubmed:publicationType
Journal Article